Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated

NOVAVAX INC

COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.
Both candidates well tolerated; >98% of solicited adverse events mild or moderate in severity.
Results from initial cohort of Phase 3 trial in adults 65+; similar to licensed comparators Nuvaxovid and Fluzone HD.
Novavax continues to pursue partnering opportunities to advance further development of these programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.